Hepregen Corporation announced today the issuance of a U.S. patent by the United States Patent and Trademark Office (“USPTO”) that protects a key element of the method the Company uses to manufacture its HepatoPacTM and related products. All 20 inventive claims in the original patent application were issued. This patent, entitled Systems and Methods for Micro-Contact Stamping along with Hepregen’s foundational patents, which were licensed from the Massachusetts Institute of Technology (“MIT”), ensure product protection for years to come.
Dr. Jack McGeehan, Hepregen’s Vice President of Operations and named inventor on the newly issued patent, said, “Hepregen is very pleased by the rapid and positive USPTO review of this patent application. The issued claims protect both the structure and method of use of a device absolutely essential to the reproducible manufacture of Hepregen’s unique product portfolio.”
Dr. Vincent Zurawski, Hepregen’s Chief Executive Officer, also commented, stating, “This important patent, the first issued by Hepregen, adds another picket to a fence of issued patents and patent applications licensed from MIT, all protecting the Company’s simple, elegant, ‘liver-in-a-dish’ products.” Dr. Zurawski added, “Hepregen’s pharmaceutical industry customers continue to utilize these HepatoPacTM products to mitigate risk in the drug development process and reduce the cost of bringing candidate drugs to the clinic.”